Saturday, 31 October 2026European Markets

SCATEC And NEOEN Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(vianews) - scatec (scatc.ol) is among this list of stock assets with the highest dividend rate and return on equity on the utilities sector.

financial asset price forward dividend yield return on equity
scatec (scatc.ol) kr67.40 2.78% 11.58%
neoen (neoen.pa) €26.24 0.5% 6.44%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. scatec (scatc.ol)

2.78% forward dividend yield and 11.58% return on equity

scatec asa, together with its subsidiaries, provides renewable energy solutions worldwide. the company operates through power production; services; and development & construction segments. it produces and sells solar, winds, and hydro generated electricity. the company also develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. the company is also involved in the engineering, procurement, and construction, as well as operation, maintenance, and asset management of power plants. it has a total of 4.2 gw in operation and under construction. the company was formerly known as scatec solar asa and changed its name to scatec asa in november 2020. scatec asa was incorporated in 2007 and is headquartered in oslo, norway.

earnings per share

as for profitability, scatec has a trailing twelve months eps of kr3.95.

pe ratio

scatec has a trailing twelve months price to earnings ratio of 17.06. meaning, the purchaser of the share is investing kr17.06 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.58%.

more news about scatec.

2. neoen (neoen.pa)

0.5% forward dividend yield and 6.44% return on equity

neoen s.a., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. the company operates through solar power, wind power, storage, farm-down, development and investments, and eliminations segments. it operates in argentina, australia, canada, ecuador, the united states, finland, france, ireland, italy, jamaica, mexico, mozambique, portugal, el salvador, sweden, and zambia. neoen s.a. was incorporated in 2008 and is headquartered in paris, france.

earnings per share

as for profitability, neoen has a trailing twelve months eps of €0.94.

pe ratio

neoen has a trailing twelve months price to earnings ratio of 27.91. meaning, the purchaser of the share is investing €27.91 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.44%.

more news about neoen.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com